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ABSTRACT
Parkinson’s disease (PD) is an age-associated neurodegenerative disorder hallmarked
by a loss of mesencephalic dopaminergic neurons. Accurate recapitulation of
the PD movement phenotype in animal models of the disease is critical for
understanding disease etiology and developing novel therapeutic treatments.
However, most existing behavioral assays currently applied to such animal models
fail to adequately detect and subsequently quantify the subtle changes associated
with the progressive stages of PD. In this study, we used a video-based analysis system
to develop and validate a novel protocol for tracking locomotor performance in
the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of PD.
We anticipated that (1) treated mice should use slower, shorter, and less frequent
strides and (2) that gait deficits should monotonically increase following MPTP
administration, as the effects of neurodegeneration become manifest. Video-based
biomechanical analyses, utilizing behavioral measures motivated by the comparative
biomechanics literature, were used to quantify gait dynamics over a seven-day period
following MPTP treatment. Analyses revealed shuﬄing behaviors consistent with
the gait symptoms of advanced PD in humans. Here we also document dramatic
gender-based differences in locomotor performance during the progression of
the MPTP-induced lesion, despite male and female mice showing similar losses of
striatal dopaminergic cells following MPTP administration. Whereas female mice
appeared to be protected against gait deficits, males showed multiple changes in gait
kinematics, consistent with the loss of locomotor agility and stability. Overall, these
data show that the novel video analysis protocol presented here is a robust method
capable of detecting subtle changes in gait biomechanics in a mouse model of PD.
Our findings indicate that this method is a useful means by which to easily and
economically screen preclinical therapeutic compounds for protecting against or
reversing neuropathology associated with PD neurodegeneration.
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INTRODUCTION
Parkinson’s disease (PD) is an age-related neurodegenerative disease, where individuals
aged older than 60 years of age show increased risk of developing the disorder (Connolly &
Lang, 2014). A triad of classical motor symptoms is seen in advanced PD patients, consist-
ing of rigidity, akinesia, and tremor (DeLong &Wichmann, 2009). These symptoms appear
following the loss of at least 80% of the dopaminergic neurons within the Substantia
Nigra pars compacta (SNpc) (Hartmann, 2004), thereby impairing a patient’s ability to
perform everyday tasks (Aviles-Olmos et al., 2013). As the disease progresses, co-morbid
non-motor symptomsmanifest, including cognitive impairments and depression (Lawson
et al., 2014; Obeso et al., 2014), which are often resistant to dopamine (DA) replacement
therapies (Connolly & Lang, 2014). Currently available therapies are mainly aimed at
replacing the lost striatal DA content. With dopaminergic cell loss continuing and the
side-effects associated with synthetic DA replacement increasing, continuous use of
pharmacotherapeutics fails to alter disease progression (Connolly & Lang, 2014). On
the other hand, deep brain stimulation (DBS) therapy shows dramatic improvements
in some late-stage PD patients, including improved gait and postural instability following
DBS implanted in the pedunculopontine nucleus (PPN), arguing strongly for a case that
patients might benefit substantially more, should intervention be initiated at an earlier
stage of the disease progression (Mazzone et al., 2014). Related to this, recent work revealed
that DBS targeting the subthalamic nucleus (STN) induces vascular remodeling effects,
including an upregulation of the vascular endothelial growth factor (VEGF), suggesting
that DBS induces plasticity-related effects (Pienaar et al., 2015). Hence, optimization of
intervention protocols stand to benefit greatly from a reliable animal model of PD that
mimics progressive stages of the disease, in line with the clinical aim of initiating treatment
at an earlier stage during progressive PD.
Accurate recapitulation of the movement phenotype seen in PD patients in animals
is important for the assessment and development of novel therapeutic treatments as
well as for providing a tool by which to gain insights into the molecular and cellular
mechanisms contributing to the loss of neurons and the concomitant circuit disruptions
that characterize human PD. In this regard, sensitive behavioral paradigms are of
paramount importance for characterizing existing and newly introduced genetic-based
and toxin-induced animal models of neurodegenerative disease (Bury & Pienaar, 2013;
Pienaar, Lu & Schallert, 2012). Unfortunately, many of the behavioral assays applied to
animal models fail to adequately detect the subtle changes associated with the different
stages of the disease (Antony, Diederich & Balling, 2011; Meredith & Rademacher,
2011). In this study, we used a novel video-based paradigm for analyzing gait and
locomotor kinematics to detect the subtle longitudinal changes in locomotor performance
occurring in the methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model
of PD, and analyzed the results in a gender-specific manner. Mice and non-human
primates systemically injected with MPTP, a mitochondrial neurotoxin, show loss of
mesencephalic dopaminergic neurons with concomitant loss of striatal DA content,
resulting in motor deficits (Bezard & Przedborski, 2011; Pienaar, Lu & Schallert, 2012;
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Schmidt & Ferger, 2001).We anticipated that (1)MPTP-treatedmice shouldmove at slower
speeds and with shorter, less frequent strides, mimicking the bradykinesia shown by PD
patients (Fernagut et al., 2002) and that (2) gait deficits should monotonically increase
following MPTP administration, as the effects of neurodegeneration become manifest
(Klemann et al., 2015). Finally, we also tested for a gender effect in the locomotor response
to MPTP treatment, given that previous research has established sex-based differences in
the phenotype of both PD patients and rodent models of the disease (Antzoulatos et al.,
2010;Gillies et al., 2014;VanDen Eeden et al., 2003).
MATERIALS AND METHODS
Study design
Research was carried out at Northeast Ohio Medical University (NEOMED), in strict
accordance with the recommendations in the Guide for the Care and Use of Laboratory
Animals of the National Institutes of Health. All procedures were pre-approved by the
NEOMED Institutional Animal Care and Use Committee (NEOMED IACUC Protocol
10-006).
Three cohorts of C57BL/6J laboratory mice (n= 4 per group, each consisting of 2 males
and 2 females) were used. One male mouse from the first cohort and one female mouse
from the second cohort did not show the characteristic striatal DA depletion following
MPTP treatment. Additionally, one female mouse from the third cohort lost a significant
amount of body weight following MPTP treatment and was removed from the study.
Therefore, our final sample consisted of nine mice (five males and four females). On
average, male mice weighed more than the female mice (mean female body mass [95%
confidence limits]: 23.7 g [23.02 g, 24.32 g], mean male body mass: 29.1 g [27.56 g,
30.66 g]; measured prior toMPTP treatment).
The three cohorts were tested in chronological order, such that at the start of data
collection, the mice in cohort 1 were 12 weeks of age, those in cohort 2 were 14 weeks
of age, and those in cohort 3 were 16 weeks of age. Following a training period lasting
from 3 to 4 days, during which mice were acclimated to the experimental procedure, each
animal was evaluated in an initial behavioral assessment to quantify baseline locomotor
performance. Following this baseline assessment, mice were treated with a single dose of
MPTP (35mg/kg; i.p.) and then evaluated for seven days of longitudinal locomotor testing,
starting at the first day post treatment, but at least 24 h after MPTP treatment to bypass
some of the most acute phenotypic effects due to the drug’s toxicity (e.g., epilepsy-like
symptoms:Klemann et al., 2015). In addition to the baseline evaluation, everymouse in the
dataset was evaluated at the seventh day after treatment. However, to improve the efficiency
of our data collection and reduce the activity burden on the mice, on the remaining days
(i.e., days 1–6 following MPTP treatment) experiments were staggered to ensure that we
collected data from at least two cohorts of mice per experimental day (i.e., cohort 1 was
evaluated on days 1–4, cohort 2 on days 1, 2, 5, 6, and cohort 3 on days 3–6). Mice were
then euthanized via cervical dislocation, the striata removed and the DA levels determined
using high-pressure liquid chromatography (HPLC), described below.
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We chose not to include a “sham” control group in our experimental design, but to
rather use mixed-model repeated measures statistical analyses (detailed below) to test
for the gait-related sequelae of MPTP treatment against each individual’s pre-treatment
baseline. This design reduced the number of animals required for our study, satisfying
ethical concerns relating to reducing the number of animal subjects used for achieving
robust statistical results. Our statistical design was combined with an intensive data
collection protocol (15–25 locomotor trials collected per day, per experimental animal),
enabling us to accurately characterize the efficacy of our new method and obtain
statistically significant results, despite a relatively small sample size.
Apparatus and locomotor testing
The mice were made to run along a white wooden trackway (41.75 cm long, 4 cm wide)
into a dark box located at the terminal end of the track. The trackway was placed on
a laboratory bench top, approximately 1 m off the ground. Mice were filmed with a
high-speed digital camera (MotionScope Model PCI 1000s; Redlake MASD Inc., San
Diego, California, USA) placed overhead to allow for a dorsal view of the mouse running
along the trackway. Videos were recorded at 200 frames per second (fps) with a 1/2,000
shutter speed. The trackway was illuminated with a 250-watt quartz light (Lowel-Light
Manufacturing Inc., Brooklyn, New York, USA) to provide adequate depth of field. On
either side of the runway, mirrors were placed at 45◦ angles to the sagittal plane to provide
complete views of the footfalls of each limb during locomotion (Fig. 1).We recorded 15–25
strides per mouse per day. All testing took place between 10AM and 2PM, during the active
(dark) phase of these nocturnal animals.
Analyses of locomotor performance
The recorded sequences were ported into ProAnalyst motion analysis software (Xcitex
Inc., Woburn, Massachusetts, USA) for off-line analyses. We marked the touchdown
and lift-off of each forelimb and hindlimb, recognizing touchdown as the first frame in
which the limb contacted the runway and lift-off as the first subsequent frame in which
the limb was no longer in contact. Individual locomotor strides were identified based
on the touchdown of a reference limb (e.g., from a touchdown of the left hindlimb to
the next touchdown of the same limb). Only “symmetrical” walking and running strides
were included in the final dataset, excluding all high-speed “asymmetrical” bounding and
galloping strides (Hildebrand, 1965). Strides during which a mouse walked on the side
mirrors were excluded from the dataset. Overall, approximately 80% of recorded strides
were included in the final dataset.
We digitized the two-dimensional position of the tip of the nose and the base of the tail
across each pass down the runway. To mitigate digitizing errors and interpolate feature
positions across occluded frames, each digitized feature was fit to a quintic smoothing
spline function (tolerance: 1 mm2) using MATLAB (version R2014b; MathWorks, Natick,
Massachusetts, USA) (Walker, 1998). In order to measure an individual animal’s net
movement trajectory, we modeled mice as point masses localized at the average static
center of mass (COM) position for each gender. Measurements of static COM position in
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Figure 1 Sample frame from high-speed video analyses of mouse locomotion. Video analysis software
was used to digitize the two-dimensional position of the nose and tail base during the pass down the
trackway. A pair of mirrors angled at 45◦ to the sagittal plane allowed for capturing touchdown and
lift-off events over complete gait cycles.
cadaveric male and female mice (N = 3males andN = 2 females) using the reaction board
method (Ozkaya & Nordin, 1999; Young, 2012) showed some variation between genders,
but little variation between individuals within genders (male mean COM position: 41.5%
of nose-to-tail base length, coefficient of variation: 6.9%; female mean COM position
45.5% of nose to tail length, coefficient of variation 3.1%). The COMwas therefore defined
as a point 41.5% along the length of the nose-to-tail base vector in males and 45.5% along
the length of the nose-to-tail base vector in females.
Although our proxy is necessarily a simplification of actual COM position, which can
be expected to vary based on both body configuration during locomotion, variation in
the effective length of the trunk (i.e., the euclidean distance between the nose and the
tail base) was minimal during locomotor strides (average coefficient of variation with
95% confidence bounds, 4.08% [3.822%, 4.337%] in males, 3.81% [3.507%, 4.114%] in
females). These data suggest that little lateral flexion of the vertebral column had occurred
and indicate that our approach of modeling the trunk as a linear vector should have
minimal effect on the accuracy of our COM estimates.
Raw data on footfall timings and modeled COM displacements were used to calculate
several metrics of locomotor performance. Average locomotor speed (cm/s) was calculated
as the absolute value of mean velocity across the stride. Stride length (cm) was defined
as the net distance travelled by the COM during the stride. Stride frequency (Hz) was
calculated as the inverse of stride duration. Additionally, we calculated two metrics of
overall postural stability. First, based on the timings of limb touchdown and liftoff events,
we calculated the percentage of stride duration spent in various support combinations
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(e.g., supported by one, two, three or four limbs). We then calculated the mean support
number using the equation: % single-limb support + (2 × % double-limb support)
+ (3 × % triple-limb support) + (4 × % quadruple-limb support). A higher mean
support number indicates that a greater number of limbs provide support at any one
instance during the stride, theoretically conferring greater postural stability to the animal.
Additionally, we calculated a “sway” index to quantify mediolateral stability, based on
the “straightness” index of Jamon & Clarac (1998). The sway index was computed as the
ratio of the total horizontal path distance travelled by the COM during the stride and the
straight-line distance between the COM coordinates at the beginning and the end of the
stride, multiplied by 100. A sway index of 100 indicates a perfectly linear path with higher
values indicating increasing amounts of mediolateral sway.
DA content analysis
We measured remaining levels of DA following systemic MPTP treatment, as previously
described (Geldenhuys et al., 2014). In brief, mice were euthanized via cervical dislocation,
the brain was removed from the skull, and striatal tissue was dissected out then snap
frozen in liquid nitrogen. For processing, the striatal tissue was weighed and placed in cold
perchloric acid (0.1 , 500 µL, 4 ◦C). Tissue samples were sonicated and centrifuged.
An aliquot was removed to measure DA levels within the bilateral striata across the
various cohorts. Tissue samples were evaluated for DA content by means of HPLC
coupled with electrochemical detection. Biogenic amines were separated on a Supelco
column (Discovery C18, 10 cm × 3 mm × 5 µm). Samples were injected into a 20 µL
loop. A degassed isogradient mobile phase consisting of sodium acetate (50 mM),
citric acid (27.4 mM), sodium hydroxide (10 mM), sodium octyl sulfate (0.1 mM),
ethylenediaminetetraacetic acid (EDTA) (0.1 mM) and 5%methanol in filtered deionized
water was used for the system. The mobile phase was adjusted to a final pH of 4.5 with the
addition of NaOH, with was and filtered (0.45 µm, Millipore filter; Millipore, Billerica,
Massachusetts, USA) prior to use. Standards were diluted in perchloric acid (0.1 ) in
increments of 3.1, 6.2, 12.5, 25, 50, 100, 200, and 400 pg/20 µL. Samples were analyzed by
using the Chromelian 6.8 software program (Dionex, Sunnyvale, California, USA). The
assay sensitivity (6.2–12.5 pg/20 µL) was determined by observing reliable peaks above
baseline noise. Striatal DA values were compared to DA levels in a vehicle-control group of
six mice (three males and three females) made up of littermates from the three cohorts of
MPTP-treatedmice (i.e., onemale and one female from each cohort).
Statistical analysis
We used a rank-based Student’s t-test with the Welch–Satthewaite correction for
heteroscedasticity to compare DA loss between genders. This method was recommended
by Ruxton (2006) as the most robust method for two-group mean comparisons. We used
linear mixed-effects Analyses of Covariance (ANCOVA) to test for gender differences in
the longitudinal effects of MPTP toxicity on locomotor performance. The mixed-effects
model allowed us to incorporate all relevant fixed factors into our analyses (i.e., gender
and days since MPTP treatment), whilst controlling for random variation amongst the
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Table 1 Sample sizes of locomotor strides, grouped by gender andMPTP treatment day.
MPTP treatment day
Baseline Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7
Female 56 40 28 23 24 39 35 42
Male 68 43 30 29 39 53 56 64
mice within each gender group (Batka et al., 2014). All measures were averaged across
strides within each experimental day for each mouse, so that the unit of analysis was
set as the average response of each mouse on each day of testing. We fitted a full model
for each measure, testing for (1) a main effect of gender, (2) a significant association
with the number of days since MPTP treatment and (3) an interaction between gender
and the number of days since MPTP treatment. A significant interaction indicates that
males and females responded differently to MPTP toxicity. In this case, we report separate
gender-specific regression slopes (and 95% confidence intervals on those slopes) in order
to better illustrate the magnitude and direction of the interaction effect. Additionally, due
to the pervasive influence of locomotor speed on most measures of rodent locomotor
performance (Batka et al., 2014), in the event of a significant gender-specific regression,
we reanalyzed the relationship between the performance variable and the days sinceMPTP
treatment with speed included as a covariate in the model. In these cases, any significant
residual association between a performance variable and the days since MPTP treatment
indicates that the indicated change in gait mechanics is not simply an after-effect of mice
changing their average locomotor speed. All statistical analyses were performed using the
R statistical package (R Core Team, 2013), including the nlme (Pinheiro et al., 2013) and
lsmeans (Lenth, 2014) add-on packages.
RESULTS
Striatal DA levels
Relative to control values, striatal DA levels inMPTP-treated mice decreased by an average
of 54.8% amongst treated males and 58.8% amongst treated females (Fig. 2). Although
striatal DA values in both genders were significantly lower than those in the vehicle control
group (males: t[4] = −7.8, p = 0.001; female: t[3] = −7.7, p = 0.005), loss of striatal DA
was statistically similar between genders (t[7] = 0.48, p= 0.64).
Locomotor performance
A total of 668 symmetrical strides were analyzed for this study (287 strides from female
mice, 381 strides frommale mice). A breakdown of the number of strides coded for each
experiment day and grouped by gender is provided in Table 1. Variation in the number of
valid strides available for analysis on each day accounts for the unequal number of strides
across the tabular cells.
Mixed-effects analyses of covariance indicated significant gender-by-days-since-MPTP-
treatment interaction for all variables (p ≤ 0.029; results summarized in Table 2). In each
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Figure 2 Measures of striatal DA levels in male and female mice. Each bar represents mean ± S.D. (N
females= 4,N males= 5). Asterisks indicate that DA levels in treatedmales and females were significantly
lower than in the vehicle-control group (p < 0.01 for both genders).
Table 2 Analyses of covariance of locomotor performance variables by gender and MPTP treatment
day.
Variable Interaction effecta Slope [95% confidence interval]b
Speed −1.87
F[1,43] = 7.93
p= 0.007
Female slope: 0.616 [−0.373, 1.61]
Male slope:−1.25 [−2.15,−0.351]
Stride length −0.0998
F[1,43] = 7.69
p= 0.008
Female slope: 0.0365 [−0.0173, 0.0902]
Male slope:−0.0633 [−0.112,−0.0145]
Stride frequency −0.136
F[1,43] = 7.05
p= 0.011
Female slope: 0.0412 [−0.0351, 0.118]
Male slope:−0.0945 [−0.164,−0.0252]
Mean support
number
0.0254
F[1,43] = 5.07
p= 0.030
Female slope: 0.00355 [−0.0133, 0.0204]
Male slope: 0.0290 [0.0136, 0.0443]
Sway index −0.0539
F[1,43] = 8.5
p= 0.006
Female slope: 0.00996 [−0.0176, 0.0375]
Male slope:−0.0439 [−0.0689,−0.0189]
Notes.
a The interaction effect indicates the average difference in slope between male and female mice (i.e., male slope–female
slope), and the significance of this difference relative to the null expectation of zero. Significant interactions are indicated
by a p-value in printed in bold type.
b These values indicate the gender specific slope of the performance variable againstMPTP treatment day. 95% confidence
intervals are displayed as [lower confidence bound, upper confidence bound]. Confidence bounds of opposite sign
indicate a non-significant slope.
case, post-hoc analysis of gender-specific regression slopes indicated that the locomotor
performance of males significantly changed following MPTP administration, whereas
females showed no significant response to MPTP treatment (i.e., the 95% confidence
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Figure 3 Longitudinal changes in locomotor performance following MPTP administration in male
and female mice. Panels show the individual mean values of (A) speed, (B) stride length, (C) stride
frequency, (D) mean support number and (E) sway index at baseline (BL) at each day following MPTP
treatment. Trend lines indicate gender-specific linear mixed-effects regression slopes.
intervals about the female slopes encompassed zero). Male mice responded to MPTP
toxicity by decreasing speed, taking shorter and fewer strides (i.e., decreasing stride
length and frequency), increasing the average number of supporting limbs on the ground
during the stride (i.e., increasingmean support number) and decreasingmediolateral sway
(i.e., lower sway indices) (Table 2 and Fig. 3).
Because speed has been shown to exert a pervasive influence on other measures of
locomotor performance in rodents (Batka et al., 2014), we reassessed the significant
relationships between the number of days following MPTP treatment and stride length,
stride frequency, mean support number, and sway index in the male mice, whilst
controlling for speed using linear mixed-effects multiple regression (results summarized in
Table 3). All four variables were significantly associated with speed (p < 0.001), suggesting
that longitudinal changes in speed may have affected other measures of locomotor
performance. Indeed, after controlling for speed, longitudinal decreases in stride length
and stride frequency were found to no longer reach statistical significance (p ≥ 0.415).
In contrast, longitudinal changes in mean support number and sway index remained
significant even after including speed as a covariate in themodel (all p≤ 0.032).
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Table 3 Association between locomotor performance variables andMPTP treatment day, controlling
for speed.
Variable Partial regression coefficient
[95% confidence interval]a
Stride length −0.016 [−0.0554, 0.0237]
p= 0.415
Stride frequency −0.002 [−0.0254, 0.0209]
p= 0.842
Mean support number 0.010 [0.0001, 0.0196]
p= 0.032
Sway index −0.012 [−0.0214,−0.0018]
p= 0.022
Notes.
a The partial regression coefficients reflect the residual influence of MPTP treatment day on each locomotor performance
variable, controlling for the effects of speed. Significant partial regressions are indicated by a p-value in printed in bold
type.
DISCUSSION
Tests designed to economically and accurately assess gait function in PD animal models
are currently lacking (but see Amende et al., 2005). Sensitive assessment tools capable
of capturing the different stages of PD in well-established animal models of the human
condition remain a challenge to PD researchers interested in screening and developing
treatments and diagnostic markers for translational use (Pienaar, Lu & Schallert, 2012).
Here we show that videography-based measurements of gait kinematics represent a robust
method to assess behavioral deficits in a well-validatedmousemodel of PD. In PD patients,
alterations in the functioning of the nigrostriatal dopaminergic system (NSDA) manifest
as changes in sensorimotor functions (DeLong & Wichmann, 2009). In mice, PD can
be modeled to a remarkably accurate extent with systematic treatment of the relatively
selective NSDA neurotoxin, MPTP. A potential drawback of this model is that seeing early
changes in themotor behavior of mice when treated withMPTPmay be difficult to observe
(Blandini & Armentero, 2012; Bove & Perier, 2012;Morin, Jourdain & Di Paolo, 2014; Tieu,
2011). One possible explanation for this difficulty in detecting early motor changes in
mice is that current behavioral assays employed by PD researchers are insensitive to the
subtle behavioral changes shown by genetic-based or toxin-induced animal models of
human PD (Pienaar, Lu & Schallert, 2012). These metrics, which typically include gait
measures (e.g., stride length: Fernagut et al., 2002), the pole test (i.e., time required to
descend a given pole:Matsuura et al., 1997) for assessing bradykinesia, performance on
a rotarod spindle for measuring balance, grip strength and motor coordination (Rozas,
Guerra & Labandeira-Garc´ıa, 1997), and a balancing test assessed by means of a beam
walking task (McDermott et al., 1994). However, these tests provide only a gross assessment
of sensorimotor function, with little distinction made between the precise functional
impairments. Additionally, in many of these assays, rodents are required to perform
tasks that are outside of their natural locomotor behavior, making it difficult to see subtle
changes in function.
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Accordingly, marked benefits could ensue with the use of novel approaches and
perspectives for the study of motor behavior in animal models of PD. In particular, detailed
analyses of gait and balance during normal rodent locomotion promise to reveal subtle
changes in motor behavior that may be difficult to detect using common techniques
(Wang et al., 2012). Moreover, such analyses have the potential to better model the bradyki-
nesia (slowed movements), festination (short, shuﬄing steps), postural abnormality,
and gait instability that characterizes PD patients. The significance of such an approach
is the prospective for identifying specific sensorimotor behavioral markers of NSDA
neurodegeneration. Since symptoms associated with PD are not evident until advanced
stages of NSDA neurodegeneration, the possibility for identifying behavioral changes at
an earlier stage of lesion progression in animal models of PD may permit more accurate
screening of novel drugs or stimulatory implants, informing our understanding of the
etiology of the human form of the disease and leading tomore promising treatments.
One approach for performing such sophisticated analyses of motor behavior consists of
the biomechanical analysis of gait dynamics. Recently,Wang and others (2012) commented
that gait measures specifically focusing on murine models of PD are currently lacking in
the literature. The precise, quantitative descriptions of animal movement presented in
this study have the potential to identify more subtle behavioral outputs of motor-related
neurodegeneration than currently available locomotor assays offer. Moreover, the robust
comparative literature that currently exists on the biomechanics of animal quadrupedal
gait (Batka et al., 2014; Young, 2012) offers a solid methodological and theoretical
framework fromwhich to construct and evaluate the analyses used in our research.
The use of the video analysis system was able to give significant insights into the gait
deficits, which were subtle at times, of MPTP-induced Parkinsonian mice. In male mice,
but not in the females, there was a significant change in gait behavior following the loss
of striatal DA content (Fig. 3). Using our novel experimental protocol, we were able to
observe changes in the gait dynamics of the mice soon after MPTP administration that
correlated with the bradykinesia and hyper-rigidity seen in PD patients (Hanakawa et
al., 1999). Specifically, following MPTP administration, male mice used slower, shorter
and less frequent strides, selected footfall patterns that ensured a greater number of
supporting limbs across the stride and decreased mediolateral sway (Fig. 3). The gait
deficits seen in the male mice became more pronounced throughout the period following
MPTP treatment, indicating a longitudinal decrease in locomotor performance as the
neurodegenerative effects of MPTP-toxicity became more pronounced (Klemann et al.,
2015). Although loss in stride length and frequency appeared to be side effects of the
general decrease in locomotor speed, longitudinal changes in mean support number and
sway index took place independently of the changes in locomotor speed (Table 3). The
longitudinal increase in mean support number suggests that male mice altered their gait in
some way to ensure that a greater number of limbs contacted the floor surface throughout
the stride, serving as a compensatory effect for promoting greater gait control, to likely be
an attempt at increasing locomotor stability. Similarly, the longitudinal decline in the sway
index may indicate a decreased ability to cope with challenges to mediolateral stability, as
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recently demonstrated in human PD patients (Galna, Murphy &Morris, 2013). Although
it is possible that some of the gait changes observed during the first 1–2 days post-injection
could have been associated with an acute inflammatory response to MPTP, subsequent
deficits in locomotor performance are best explained as sequelae of neurodegeneration,
mimicking the phenotypic processes that occur during human PD (Klemann et al., 2015),
mimicking the phenotypic processes that occur during human PD.
Interestingly, MPTP-treated female mice showed a dramatic difference in response
to the MPTP toxicity. Taking all of the results into account, female mice showed a
delayed and diminished response to MPTP on gait function, agreeing with findings that
premenopausal women are at lower risk of developing Parkinsonism (Van Den Eeden et al.,
2003), and that the clinical phenotype of PD in women often shows a delayed presentation
that is reduced in severity when compared to men (Gillies et al., 2014). Our findings are
also in agreement with previous studies on the gender bias in MPTP treated mice
(Antzoulatos et al., 2010).
Although the posthumous processing of striatal tissue indicated similar percent losses
of dopaminergic neurons in males and females in response to MPTP, C57BL/6J females
typically show substantially greater absolute levels of striatal DA (Dluzen, McDermott &
Liu, 1996). Accordingly, a critical absolute concentration of DA may remain in females
to enable their relatively better gait performance. It is also likely that the observed gender
differences in gait dysfunction are due to compensatory processes unique to females.
Specifically, estradiol has been shown to promote DA turnover, -synthesis, and -release,
while simultaneously suppressing reuptake, providing a sex-specific buffering mechanism
for preserving behavioral function despite the depletion of dopaminergic populations
of neurons (Dluzen & Horstink, 2003; Gillies et al., 2014). While estrogen is capable
of producing neuroprotection against MPTP in both male and female C57BL/6J mice
(Dluzen, McDermott & Liu, 1996), the greater endogenous levels of estrogen along with
greater basal striatal DA concentrations of females may contribute to such compensatory
processes resulting in amaintenance of female performance in our locomotor task.
CONCLUSIONS
Economical tests designed to accurately assess natural gait function in PD animal
models are currently lacking. Here we illustrate the ability of a novel testing protocol
using video-based analysis of movement to provide insight into the gait performance
of MPTP-treated mice. We were able to show changes in gait function in early stages
following MPTP treatment. The male group showed a statistically significant higher
propensity towards gait changes than the female mice, suggesting that gait deficits in
female MPTP-treated mice might be subtler. Future work should consider carrying out
the described gait analyses in a cross-sectional manner, allowing for repeated assays of
striatal DA content following MPTP administration to facilitate more precise testing for
possible associations between striatal DA depletion and locomotor dysfunction. Overall,
the results of our study demonstrate clearly that the novel methodology proposed here
has the potential to precisely quantify gait changes in animal models of PD. As such, our
Geldenhuys et al. (2015), PeerJ, DOI 10.7717/peerj.1175 12/16
measures could be used as output metrics in the initial screening and optimization of
compounds and surgical interventions for slowing, or even reversing, disease progression.
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